Loading…
← CockpitCompetitor Analysis › 2190.HK Zylox-Tonbridge Medical Technology Co., Ltd. Class HOpen in the cockpit ↗

Zylox-Tonbridge Medical Technology Co., Ltd. Class H2190.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Momentum neutral 50
Mkt cap
$768M
US dollars, full cap
Free float
45%
of shares outstanding
$/day
$935,928
20-day average traded
Fwd P/E
14.4×
forward earnings
ROIC−WACC
+3.6 pp
WACC 8.8%
Hurdle
-102 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · HKDHK$17.90
1D-2.8%
1W-4.1%
1M-12.7%
3M-8.2%
6M-15.8%
YTD-22.5%
1Y-24.9%
ATR %4.9%
52w lowhigh36.1% off high

What Zylox-Tonbridge Medical Technology does

Employees: 925

Zylox-Tonbridge Medical Technology at a glance

Size Zylox-Tonbridge Medical Technology (2190.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $768M, the 645th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$17.90 on 18 Nov 2026.

Performance Over six months the shares fell 15.8%, against -12.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 39.3% over the last twelve months (peer median +10.2%); the operating margin is 24.7% (peer median 11.4%).

Valuation It trades at 14.4× forward earnings against a peer median of 20.2× (3rd cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +106%, so the hurdle is -102 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.6 points above its cost of capital (8.8% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026Peer median 892190.HK 86
Six months, rebased to 100: Zylox-Tonbridge Medical Technology against the median of its 20 peers (local-currency closes).

Zylox-Tonbridge Medical Technology financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.35BHK$1.15BHK$848MHK$583MHK$389M
Revenue growth—+35%+45%+50%—
Gross profitHK$963MHK$806MHK$587MHK$400MHK$271M
EBITDAHK$380MHK$260MHK$110M-HK$131M-HK$238M
Net incomeHK$342MHK$265MHK$109M-HK$87.0M-HK$132M
Free cash flowHK$417MHK$299M-HK$20.2M-HK$104M-HK$262M
Capital expenditureHK$104MHK$121MHK$207MHK$211MHK$169M
Total debtn/aHK$70.9MHK$96.7MHK$61.5MHK$15.7M

Quarterly statements and history in the cockpit →

Zylox-Tonbridge Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%VREX1302CTKBMLAB300463BBNXSETL688108002950300453603108INMD600855301367688179096530AMSMCAP6880683011222190.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Zylox-Tonbridge Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×VREX13023004636881083004536031083013676881790965303011222190.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zylox-Tonbridge Medical Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%1302MLAB300463688108300453603108INMD0965302190.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zylox-Tonbridge Medical Technology is the large dot.

Zylox-Tonbridge Medical Technology competitors and peer comparison

How Zylox-Tonbridge Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zylox-Tonbridge Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure2190.HKPeer medianRank in peer set
1-month return-12.7%-8.5%8th lowest of 21
6-month return-15.8%-12.4%11th highest of 21
Distance from 52-week high-36.1%-40.6%9th highest of 21
Revenue growth (TTM)+39.3%+10.2%4th highest of 21
Operating margin24.7%11.4%highest of 21
Forward P/E14.4×20.2×3rd cheapest of 15
Growth the price implies (Req g, 7 yrs)3.8%8.8%6th least demanding of 13
Growth delivered (Del g)+105.8%+12.8%highest of 13
Hurdle (Req g minus delivered)-102.0 pp-3.7 ppleast demanding of 13
ROIC minus cost of capital+3.6 pp-2.5 pp5th highest of 21
EV / EBITDA12.7×14.7×4th cheapest of 9
Net debt / EBITDA-3.3×0.2×3rd least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a

Questions

Which companies are Zylox-Tonbridge Medical Technology's closest peers?
The cockpit's peer set: Varex Imaging (VREX), LifeTech Scientific (1302.HK), Cytek Biosciences (CTKB), Mesa Laboratories (MLAB), Maccura Biotechnology (300463.SZ), Beta Bionics (BBNX), Standard Engineering Technology (SETL.NS), Sino Medical Sciences Technology (688108.SS).
Is Zylox-Tonbridge Medical Technology expensive compared with its peers?
On forward p/e it trades at 14.4× against a peer median of 20.2×, 3rd cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +106%, so the hurdle is -102 pp: the price already allows for a slowdown.
How has Zylox-Tonbridge Medical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -15.8% against -12.4% for the median peer; over one year -24.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.